GlaxoSmithKline PLC — Director's Dealing 2018

Jan 16, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0616C

GlaxoSmithKline PLC

16 January 2018

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	87.861
£13.306	87.861
£13.306	217.580
£13.306	217.564
£13.306	236.894
£13.306	236.879

d)

Aggregated information

Aggregated volume Price

1,084.639

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	64.344
£13.306	64.344
£13.306	147.828
£13.306	123.348
£13.306	123.334

d)

Aggregated information

Aggregated volume Price

523.198

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Debruyne

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	207.321
£13.306	207.306

d)

Aggregated information

Aggregated volume Price

414.627

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	122.724
£13.306	122.707
£13.306	287.332
£13.306	287.316
£13.306	215.211
£13.306	215.211

d)

Aggregated information

Aggregated volume Price

1,250.501

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	45.052
£13.306	45.052
£13.306	106.239
£13.306	106.239
£13.306	77.966
£13.306	77.951

d)

Aggregated information

Aggregated volume Price

458.499

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 January 2018 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$36.84	87.876

d)

Aggregated information

Aggregated volume Price

87.876

$36.84

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	72.194
£13.306	72.194
£13.306	135.207
£13.306	135.207
£13.306	98.121
£13.306	98.106

d)

Aggregated information

Aggregated volume Price

611.029

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	97.174
£13.306	97.158
£13.306	197.805
£13.306	197.805
£13.306	147.686
£13.306	147.686

d)

Aggregated information

Aggregated volume Price

885.314

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	66.002
£13.306	121.024
£13.306	92.975

d)

Aggregated information

Aggregated volume Price

280.001

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 January 2018 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
$36.84	50.006
$36.84	50.006
$36.84	112.593
$36.84	112.593
$36.84	93.253
$36.84	93.239

d)

Aggregated information

Aggregated volume Price

511.690

$36.84

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P J T Vallance

b)

Position/status

President, R&D

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)	Volume(s)
£13.306	143.039
£13.306	143.039
£13.306	232.681
£13.306	232.681
£13.306	160.411
£13.306	160.411

d)

Aggregated information

Aggregated volume Price

1,072.262

£13.306

e)

Date of the transaction

2018-01-11

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDQLFFVFFZBBD